Guggenheim Securities updated their outlook on Immunovant (NASDAQ:IMVT) shares, raising the price target from $44.00 to $46.00 while maintaining a Buy rating on the stock. Currently trading at $23.23, ...

Numerous peripheral neuropathies can favor impairment of the median nerve in the carpal tunnel, such as inflammatory neuropathies (chronic inflammatory demyelinating polyneuropathy ... et al. Criteria ...

Chronic inflammatory demyelinating polyradiculoneuropathy (CIDP) is a progressive or relapsing neuropathy likely caused by an autoimmune attack on the peripheral nerves. A number of treatment ...

Patients with COVID-19 who developed chronic inflammatory demyelinating polyneuropathy (CIDP) as a complication could follow a specific pattern in medical management, according to a study published in ...

Background: Chronic inflammatory demyelinating polyradiculoneuropathy is a rare acquired immune-mediated progressive or relapsing disorder causing peripheral neuropathic disease of duration more ...

We explore the somewhat nebulous relationship between chronic inflammatory demyelinating polyneuropathy and cancer risk. Chronic inflammatory demyelinating polyneuropathy (CIDP) is characterized by ...

The criteria for assessing researchers for promotion to full professorship, and the incentives they foster vary widely around the world, says Yensi Flores Bueso, who has lived in all three countries.

According to the Academy of Motion Picture Arts and Sciences’ evolving rulebook, for a feature film to be considered for the general entry categories at the Oscars, including Best Picture, it ...

As many as two billion people suffer from it — including me. Can science finally bring us relief? Credit...Marcus Schaefer for The New York Times Supported by By Jennifer Kahn Jennifer Kahn is a ...

After developing chronic pain, I started looking into what scientists do — and still don’t — understand about the disease. Here is what I learned. By Jennifer Kahn Most of us don’t think ...